drugset / Trial / NCT01810367

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

NCT01810367 ↗

Phase 2 Completed 84 enrolled Fudan University
RandomizedParallel-groupOpen-labelTreatment

Summary

Assess the PFS/ORR/OS of ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in first Treatment of NSCLC

Timeline

Start
2011-12
Primary completion
2015-12
Completion
2015-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ABX Unknown 100 mg/m2 Intravenous
Comparator Cisplatin Other / unclassified 75 mg/m2 Intravenous
Comparator Gemcitabine Small molecule 1000 mg/m2 —